MONASH IVF GROUP LIMITED (MVF)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MVF - MONASH IVF GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.25
Index: ASX300 | ALL-ORDS

Monash IVF is an Australian provider of IVF, Ultrasound and genetic testing services throughout Australia and Asia. The company has been listed since 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.25

23 Dec
2024

0.015

OPEN

$1.24

1.21%

HIGH

$1.26

441,642

LOW

$1.23

TARGET
$1.453 16.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MDR . MPL . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
MVF: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.7 7.8 xxx
DPS (cps) xxx 5.0 5.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx 13.6% 0.0% xxx
PE Ratio xxx N/A 16.0 xxx
Dividend Yield xxx N/A 4.0% xxx
Div Pay Ratio(%) xxx N/A 64.5% xxx

Dividend yield today if purchased 3 years ago: 4.67%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 4.03

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 2.2c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.7
DPS All xxxxxxxxxxxxxxx5.0
Sales/Revenue xxxxxxxxxxxxxxx255.0 M
Book Value Per Share xxxxxxxxxxxxxxx62.1
Net Operating Cash Flow xxxxxxxxxxxxxxx50.0 M
Net Profit Margin xxxxxxxxxxxxxxx-2.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-2.53 %
Return on Invested Capital xxxxxxxxxxxxxxx-1.77 %
Return on Assets xxxxxxxxxxxxxxx-1.40 %
Return on Equity xxxxxxxxxxxxxxx-2.53 %
Return on Total Capital xxxxxxxxxxxxxxx11.02 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx10.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx8 M
Long Term Debt xxxxxxxxxxxxxxx127 M
Total Debt xxxxxxxxxxxxxxx135 M
Goodwill - Gross xxxxxxxxxxxxxxx273 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx11 M
Price To Book Value xxxxxxxxxxxxxxx2.07

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx21.7 M
Capex % of Sales xxxxxxxxxxxxxxx8.50 %
Cost of Goods Sold xxxxxxxxxxxxxxx180 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx33 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

28/11/2024

1

Buy

$1.56

24.80%

Despite the inclusion of the Fertility North acquisition, slower growth year-to-date was evident at Monash IVF's AGM, driven by a decline in stimulated cycles compared to the industry, explains Bell Potter.

The analysts note market share for Monash IVF remained flat, and new patient registrations were consistent with the prior corresponding period.

The broker observes a solid performance in the International business, though it was temporarily affected by construction at the Singapore clinic, which has now been completed.

Management guides to 1H25 underlying profit growth of 3.3% to 6.6%, below Bell Potter's previous forecast of approximately 10%.

The target price is reduced to $1.56 from $1.85. The Buy rating is maintained.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 4.80 cents and EPS of 7.20 cents.
Bell Potter forecasts a full year FY26 dividend of 5.30 cents and EPS of 8.00 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

27/08/2024

1

Overweight

$1.46

16.80%

Wilsons observes a solid second half from Monash IVF was affected by an unexpected outcome in relation to a class action. The proposed settlement necessitates further borrowing to the extent where additional interest expense negates net profit growth in FY25.

The share price reaction is "fair" and the broker asserts it opportunistically takes the "heat" out of the trading multiple. Overweight. Target is reduced to $1.46 from $1.58.

FORECAST
Wilsons forecasts a full year FY25 dividend of 5.40 cents and EPS of 7.70 cents.
Wilsons forecasts a full year FY26 dividend of 6.10 cents and EPS of 8.60 cents.
Access Extra Coverage Research History >

MVF STOCK CHART

FNArena News on MVF

1
Rudi’s View: Final Best Buys & Conviction Ideas

Dec 23 2024 - Rudi's View
2
Rudi’s View: Banks, WiseTech, Redox & Integral Diagnostics

Dec 19 2024 - Rudi's View
3
Rudi’s View: Best Buys & Smaller Cap Favourites

Dec 12 2024 - Rudi's View
4
August Result Season 2024: The Wrap

Sep 24 2024 - Feature Stories
5
Rudi’s View: Asking The Important Questions

Sep 11 2024 - Rudi's View

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia